Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria

Trial Profile

Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Agatolimod (Primary) ; Malaria vaccine (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 26 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top